This clinical biotechnology company develops antibody-protein-drug conjugates that specifically target high endothelial venules for the delivery of therapeutics to solid tumors. By enhancing the precision of drug delivery, the company aims to improve cancer treatment outcomes and facilitate early diagnosis.
Funding
$950K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often lack precision, leading to systemic toxicity and reduced efficacy due to off-target effects. Delivering therapeutics directly to solid tumors and metastatic sites remains a significant challenge.
Solution
NanoTomer, Inc. is developing targeted oncology therapies using antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs) to enhance drug delivery to tumors. Their approach involves conjugating proprietary antibodies (like MHA112) or peptides (like Protin101) to potent active pharmaceuticals. MHA112 targets a protein expressed in specialized venules within the lymphatic system that proliferate in and around solid tumors, enabling concurrent targeting of primary tumors and metastases. Protin101, a peptide fragment, also demonstrates effectiveness in targeting solid tumors and enhancing the efficacy of checkpoint inhibitors and CAR-T therapies. By increasing the specificity of drug delivery, NanoTomer aims to improve patient outcomes and reduce the side effects associated with traditional cancer treatments.
Target Audience
The primary target audience includes oncology researchers and clinicians seeking more effective and targeted cancer therapies with reduced systemic toxicity.
Features
- MHA112: An antibody-drug conjugate that targets a protein expressed in specialized venules contained in the lymphatic system, which proliferate in and around solid tumors.
- Protin101: A peptide-drug conjugate that targets solid tumors and can be conjugated to pharmaceuticals or used for endogenous activation of T-cells.
- Targeted delivery of highly potent active pharmaceuticals directly to primary tumors and metastatic sites.
- Potential uses in cancer therapy, treatment of autoimmune diseases such as IBD, and CAR-T therapy.
- Pre-clinical data in multiple solid cancer models in preparation for an IND filing with the FDA.